BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rowland KJ, Brubaker PL. Life in the crypt: A role for glucagon-like peptide-2? Molecular and Cellular Endocrinology 2008;288:63-70. [DOI: 10.1016/j.mce.2008.02.014] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Wulkersdorfer B, Kao KK, Agopian VG, Dunn JC, Wu BM, Stelzner M. Growth Factors Adsorbed on Polyglycolic Acid Mesh Augment Growth of Bioengineered Intestinal Neomucosa. Journal of Surgical Research 2011;169:169-78. [DOI: 10.1016/j.jss.2009.11.719] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
2 Yan JK, Zhang T, Dai LN, Gu BL, Zhu J, Yan WH, Cai W, Wang Y. CELF1/p53 axis: a sustained antiproliferative signal leading to villus atrophy under total parenteral nutrition. FASEB J 2019;33:3378-91. [PMID: 30514107 DOI: 10.1096/fj.201801695R] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Zorzetti N, D'Andrea V, Lauro A. Proteomic biomarkers in short bowel syndrome : are we ready to use them in clinical activity? Expert Rev Proteomics 2021;18:285-93. [PMID: 33910424 DOI: 10.1080/14789450.2021.1924063] [Reference Citation Analysis]
4 Kannen V, Garcia SB, Stopper H, Waaga-gasser AM. Glucagon-like peptide 2 in colon carcinogenesis: Possible target for anti-cancer therapy? Pharmacology & Therapeutics 2013;139:87-94. [DOI: 10.1016/j.pharmthera.2013.04.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
5 Marathe CS, Rayner CK, Jones KL, Horowitz M. Glucagon-like peptides 1 and 2 in health and disease: A review. Peptides 2013;44:75-86. [DOI: 10.1016/j.peptides.2013.01.014] [Cited by in Crossref: 54] [Cited by in F6Publishing: 48] [Article Influence: 6.0] [Reference Citation Analysis]
6 Vipperla K, O’keefe SJ. Teduglutide for the treatment of short bowel syndrome. Expert Review of Gastroenterology & Hepatology 2014;5:665-78. [DOI: 10.1586/egh.11.82] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
7 Bian Q, Chen J, Qiu W, Peng C, Song M, Sun X, Liu Y, Ding F, Chen J, Zhang L. Four targeted genes for predicting the prognosis of colorectal cancer: A bioinformatics analysis case. Oncol Lett 2019;18:5043-54. [PMID: 31612015 DOI: 10.3892/ol.2019.10866] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
8 Rowland KJ, Trivedi S, Lee D, Wan K, Kulkarni RN, Holzenberger M, Brubaker PL. Loss of glucagon-like peptide-2-induced proliferation following intestinal epithelial insulin-like growth factor-1-receptor deletion. Gastroenterology. 2011;141:2166-2175. e7. [PMID: 21925122 DOI: 10.1053/j.gastro.2011.09.014] [Cited by in Crossref: 57] [Cited by in F6Publishing: 57] [Article Influence: 5.2] [Reference Citation Analysis]
9 Hanley NA. Commonalities in the endocrinology of stem cell biology and organ regeneration. Mol Cell Endocrinol 2008;288:1-5. [PMID: 18467021 DOI: 10.1016/j.mce.2008.04.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
10 Rosendo-Silva D, Matafome P. Gut-adipose tissue crosstalk: A bridge to novel therapeutic targets in metabolic syndrome? Obes Rev 2021;22:e13130. [PMID: 32815267 DOI: 10.1111/obr.13130] [Reference Citation Analysis]
11 Thompson JS, Rochling FA, Weseman RA, Mercer DF. Current management of short bowel syndrome. Curr Probl Surg. 2012;49:52-115. [PMID: 22244264 DOI: 10.1067/j.cpsurg.2011.10.002] [Cited by in Crossref: 69] [Cited by in F6Publishing: 54] [Article Influence: 6.9] [Reference Citation Analysis]
12 Mumphrey MB, Patterson LM, Zheng H, Berthoud HR. Roux-en-Y gastric bypass surgery increases number but not density of CCK-, GLP-1-, 5-HT-, and neurotensin-expressing enteroendocrine cells in rats. Neurogastroenterol Motil. 2013;25:e70-e79. [PMID: 23095091 DOI: 10.1111/nmo.12034] [Cited by in Crossref: 104] [Cited by in F6Publishing: 93] [Article Influence: 10.4] [Reference Citation Analysis]
13 Joly F, Mayeur C, Messing B, Lavergne-slove A, Cazals-hatem D, Noordine M, Cherbuy C, Duée P, Thomas M. Morphological adaptation with preserved proliferation/transporter content in the colon of patients with short bowel syndrome. American Journal of Physiology-Gastrointestinal and Liver Physiology 2009;297:G116-23. [DOI: 10.1152/ajpgi.90657.2008] [Cited by in Crossref: 62] [Cited by in F6Publishing: 40] [Article Influence: 4.8] [Reference Citation Analysis]
14 Fischer-Tlustos AJ, Pyo J, Song Y, Renaud DL, Guan LL, Steele MA. Short communication: Effect of delaying the first colostrum feeding on small intestinal histomorphology and serum insulin-like growth factor-1 concentrations in neonatal male Holstein calves. J Dairy Sci 2020;103:12109-16. [PMID: 33041024 DOI: 10.3168/jds.2020-18966] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Zhang Z, Wu X, Cao L, Zhong Z, Zhou Y. Generation of glucagon-like peptide-2-expressing Saccharomyces cerevisiae and its improvement of the intestinal health of weaned rats. Microb Biotechnol 2016;9:846-57. [PMID: 27641625 DOI: 10.1111/1751-7915.12412] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
16 Brinkman AS, Murali SG, Hitt S, Solverson PM, Holst JJ, Ney DM. Enteral nutrients potentiate glucagon-like peptide-2 action and reduce dependence on parenteral nutrition in a rat model of human intestinal failure. Am J Physiol Gastrointest Liver Physiol 2012;303:G610-22. [PMID: 22744334 DOI: 10.1152/ajpgi.00184.2012] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
17 Wallis K, Walters JR, Gabe S. Short bowel syndrome: the role of GLP-2 on improving outcome. Curr Opin Clin Nutr Metab Care 2009;12:526-32. [PMID: 19474717 DOI: 10.1097/MCO.0b013e32832d23cd] [Cited by in Crossref: 29] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
18 Buccigrossi V, Armellino C, Ruberto E, Barone MV, Marco GD, Esposito C, Guarino A. Polar Effects on Ion Transport and Cell Proliferation Induced by GC-C Ligands in Intestinal Epithelial Cells. Pediatr Res 2011;69:17-22. [PMID: 20924314 DOI: 10.1203/PDR.0b013e3181ff61ba] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
19 Mayo BJ, Stringer AM, Bowen JM, Bateman EH, Keefe DM. Irinotecan-induced mucositis: the interactions and potential role of GLP-2 analogues. Cancer Chemother Pharmacol 2017;79:233-49. [PMID: 27770239 DOI: 10.1007/s00280-016-3165-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
20 Grigoryan M, Kedees MH, Charron MJ, Guz Y, Teitelman G. Regulation of mouse intestinal L cell progenitors proliferation by the glucagon family of peptides. Endocrinology 2012;153:3076-88. [PMID: 22569789 DOI: 10.1210/en.2012-1120] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
21 Lang S, Wei R, Wei T, Gu L, Feng J, Yan H, Yang J, Hong T. Glucagon receptor antagonism promotes the production of gut proglucagon-derived peptides in diabetic mice. Peptides 2020;131:170349. [DOI: 10.1016/j.peptides.2020.170349] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]